Obese patients requiring mechanical ventilation
Conditions
Interventions
Experimental group:Remimazolam tosilate (RMZ Rebening @, Jiangsu Hengrui Pharmaceutical Co., LTD., Chinese Medicine approval number H20190034, 36mg/ dose) was used for sedation, and remimazolam was co
Control group:Propofol (LWJ Leweijing@, Sichuan Guorui Pharmaceutical Co., LTD., Chinese Medicine approval number H20030115, 0.5g/ branch) was continuously pumped intravenously at an initial infusion
Sponsors
Dazhou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Age =18 years old; BMI =30kg/m2; The duration of tracheal intubation before enrollment was =24 hours, and it was expected that mechanical ventilation and sedation were still needed for =96 hours. Hemodynamic stability, mean arterial pressure (MAP) =65mmHg; No sedative drugs such as remimazolam tosilate were used before the experiment. Before enrollment, analgesic and sedative drugs were stopped for drug washout.
Exclusion criteria
Exclusion criteria: Women who are pregnant or lactating; Severe hemodynamic instability; Patients with abnormal heart rhythm; Patients with disturbance of consciousness or unable to complete the assessment of analgesia and sedation; Cervical spine and spinal injuries; Acute hepatitis or severe liver dysfunction (Child-Pugh class C); Severe chronic kidney disease (glomerular filtration rate < 60 ml/min/1.73m2); Alcoholism;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemodynamic changes during sedation;Success rate of sedation;Refers to oxygen saturation (SpO2);Oxygenation index (PO2/FiO2); | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of mechanical ventilation;Length of ICU stay;Average daily cost of sedatives;The dose of sedative drugs was calculated;28-day mortality; | — |
Countries
China
Contacts
Public ContactCheng Liu
Dazhou Central Hospital
Outcome results
None listed